

Special Issue

O-GlcNAcylation and Cancer

Message from the Guest Editors

Cancer is one of the leading causes of morbidity and mortality worldwide, linked in part to deteriorating environmental conditions and unsafe lifestyles. Much progress has been made in recent decades in deciphering the etiology, origin, and causes of cancer, but much remains to be done to understand the molecular mechanisms underlying its initiation and progression. In recent years, O-GlcNAcylation has been found to be particularly disturbed in oncogenic processes, irrespective of the stage or molecular process considered. In particular, because of its strategic position as a metabolic hub, this post-translational modification could play a role of switch between nutritional disorders and cancer. This Special Issue is an opportunity to take stock of current knowledge on the subject and to project research into the near future, which should shed new light into our understanding of the impact of a shaken O-GlcNAcylation homeostasis, related or not with the nutritional and environmental aspects, on cancer and anticancer therapies.

Guest Editors

Prof. Dr. Ikram El Yazidi-Belkoura

Université Lille, CNRS, UMR 8576–UGSF–Unité de Glycobiologie Structurale et Fonctionnelle, Lille, France

Prof. Dr. Tony Lefebvre

Université Lille, CNRS, UMR 8576–UGSF–Unité de Glycobiologie Structurale et Fonctionnelle, Lille, France

Deadline for manuscript submissions

closed (30 November 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/38124

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)